Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ARIPIPRAZOLE vs SURITAL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Partial agonist at D2 and 5-HT1A receptors; antagonist at 5-HT2A receptors.
SURITAL (thiamylal) is an ultra-short-acting barbiturate that enhances GABA-A receptor activity, increasing chloride ion conductance and neuronal hyperpolarization, resulting in rapid induction of anesthesia.
Schizophrenia,Acute manic and mixed episodes associated with bipolar I disorder,Maintenance treatment of bipolar I disorder,Adjunctive treatment of major depressive disorder,Irritability associated with autistic disorder,Tourette's disorder
Induction of anesthesia,Maintenance of anesthesia as part of balanced anesthesia,Adjunct to regional anesthesia,Control of convulsive states (off-label)
Oral: 10-15 mg once daily; initial and target dose 10-15 mg; maximum 30 mg/day. IM: 9.75 mg single dose, then 5.25-9.75 mg every 2 hours if needed; maximum 30 mg/day.
Induction: 3-5 mg/kg IV bolus over 10-15 seconds. Maintenance: 0.5-1.5 mg/kg IV as needed for anesthesia. Also used as 0.2-0.4% solution for IV infusion at 0.5-2 mg/min.
Aripiprazole has a terminal elimination half-life of approximately 75 hours in extensive CYP2D6 metabolizers and about 146 hours in poor metabolizers. The active metabolite, dehydro-aripiprazole, has a half-life of about 94 hours. This long half-life allows for once-daily dosing and gradual achievement of steady state (14 days in extensive metabolizers).
Terminal elimination half-life 2-8 hours (mean 4.5 h) in adults; prolonged in hepatic impairment.
Primarily hepatic via CYP2D6 and CYP3A4.
Primarily hepatic metabolism via microsomal enzyme oxidation (CYP2B6, CYP3A4) to inactive metabolites; minor renal excretion.
Aripiprazole is extensively metabolized primarily by the liver via CYP2D6 and CYP3A4. Approximately 25% of the dose is excreted unchanged in urine, and about 55% in feces. The major metabolite, dehydro-aripiprazole, accounts for about 40% of the AUC and is also excreted in urine and feces.
Primarily renal excretion of metabolites; <1% unchanged. Minor biliary/fecal elimination.
Aripiprazole is >99% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein. High protein binding means that changes in protein levels (e.g., hypoalbuminemia) can affect free drug concentration.
~70% bound to albumin.
The volume of distribution (Vd) for aripiprazole is approximately 4.9 L/kg, indicating extensive tissue distribution (well beyond total body water). This large Vd suggests significant partitioning into tissues, which contributes to the long half-life.
1.5-2.5 L/kg; indicates extensive tissue distribution.
Oral: The absolute bioavailability of aripiprazole tablets is approximately 87%. Bioavailability is not significantly affected by food. Intramuscular immediate-release: Bioavailability is 100% for the IM formulation relative to oral. The long-acting injectable (aripiprazole lauroxil) has a bioavailability of about 100% compared to oral aripiprazole after reaching steady state.
IM: ~90%.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥15 m L/min). For severe renal impairment (Cr Cl <15 m L/min), use with caution; limited data suggests no adjustment needed, but monitor tolerability.
No specific GFR-based adjustments; metabolized primarily in liver. Caution in severe renal impairment due to potential accumulation of inactive metabolites.
Child-Pugh Class A (mild): no adjustment. Child-Pugh Class B (moderate): start at 10 mg/day; titrate cautiously. Child-Pugh Class C (severe): avoid use; if unavoidable, start at 5 mg/day and titrate slowly.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 50% and titrate to effect. Child-Pugh C: Contraindicated or use with extreme caution with reduced doses (e.g., 25-50% of normal).
Schizophrenia (≥13 years): 10-15 mg/day initially; target 15 mg/day; max 30 mg/day. Irritability associated with autistic disorder (6-17 years): 5-10 mg/day; start at 2.5 mg/day for ≥30 kg and 5 mg/day for <30 kg; titrate gradually. Tourette's disorder (6-18 years): 5-10 mg/day; start at 2.5 mg/day for <50 kg and 5 mg/day for ≥50 kg; max 10 mg/day.
Induction: 3-6 mg/kg IV. Maintenance: 1-2 mg/kg IV as needed. Use with caution; not recommended for neonates.
Initiate at 10 mg/day; titrate slowly due to increased sensitivity and risk of hypotension, sedation, and extrapyramidal symptoms. Maximum 15 mg/day in elderly patients with psychosis. Consider lower initial doses (2-5 mg/day) in frail patients.
Reduce dose by 30-50% due to decreased clearance and increased sensitivity. Administer slowly and titrate to effect.
Increased risk of death in elderly patients with dementia-related psychosis.
WARNING: RESPIRATORY DEPRESSION AND CARDIAC ARREST. SURITAL may cause severe respiratory depression or apnea, especially with rapid administration. Resuscitative equipment and personnel trained in airway management must be immediately available. Avoid intra-arterial injection due to risk of arteriospasm, thrombosis, and gangrene.
Increased risk of cerebrovascular events in elderly with dementia, neuroleptic malignant syndrome, tardive dyskinesia, metabolic changes (hyperglycemia, dyslipidemia, weight gain), orthostatic hypotension, leukopenia/neutropenia, seizures, cognitive and motor impairment, and body temperature dysregulation.
Monitor respiratory and cardiac function continuously; use with caution in patients with respiratory compromise, hypotension, shock, or hepatic/renal impairment; may cause laryngospasm, bronchospasm, or hypotension; avoid extravasation; use with caution in porphyria.
Hypersensitivity to aripiprazole or any components of the formulation.
Absolute: Known hypersensitivity to barbiturates, acute intermittent porphyria, severe respiratory insufficiency, status asthmaticus, and conditions where general anesthesia is contraindicated.
No significant food interactions. Absorption unaffected by food. Avoid grapefruit juice as it may increase aripiprazole levels via CYP3A4 inhibition.
No specific food interactions reported for Surital (thiamylal). However, patients should avoid consuming grapefruit or grapefruit juice for 24 hours before and after administration, as it may theoretically inhibit cytochrome P450 metabolism, although significant interactions are not well-documented.
First trimester: Limited human data; animal studies show no teratogenicity at therapeutic doses, but increased risk of neural tube defects at high doses. Second/third trimesters: Possible risk of extrapyramidal symptoms or withdrawal in neonates; risk of gestational diabetes and weight gain. Overall, not a major human teratogen but risk-benefit assessment required.
Pregnancy Category D (positive evidence of human fetal risk). First trimester: Risk of congenital anomalies (limb defects, CNS malformations) based on animal studies and limited human data. Second/third trimester: Increased risk of preterm labor, fetal bradycardia, neonatal respiratory depression, and withdrawal syndrome. Avoid use during pregnancy unless clearly needed.
Aripiprazole is excreted into breast milk; estimated relative infant dose is 1-8% of maternal weight-adjusted dose. M/P ratio not established. Monitor infant for sedation, poor feeding, and extrapyramidal symptoms. Consider benefits of breastfeeding vs. potential risks.
Excretion into breast milk is unknown; M/P ratio not established. Due to high lipid solubility, potential for significant transfer. Consider risks of neonatal CNS depression. Use with caution; monitor infant for sedation, poor feeding, and respiratory depression. Alternative agents preferred.
Increased clearance and volume of distribution in pregnancy may necessitate dose increases, especially in the third trimester. Therapeutic drug monitoring if available; adjust based on clinical response and tolerability. Postpartum, reduce to prepregnancy dose to avoid toxicity.
Increased volume of distribution and hepatic metabolism in pregnancy may require higher induction doses and more frequent maintenance doses. However, due to fetal risks, avoid use in pregnancy unless absolutely necessary. If used, start at lower range (e.g., 3-4 mg/kg IV induction) and titrate to effect. No established dose adjustment guidelines; individualize based on clinical response and close monitoring.
Aripiprazole is a partial dopamine agonist, distinguishing it from typical antipsychotics. Monitor for akathisia, especially during titration. QT prolongation risk is lower than with other antipsychotics, but ECG is recommended in patients with cardiac risk. Tardive dyskinesia risk exists but may be lower than with typical agents. Avoid abrupt discontinuation to prevent withdrawal dyskinesias. Metabolized by CYP2D6 and CYP3A4; dose adjustments needed with CYP2D6 inhibitors or poor metabolizers. May cause orthostatic hypotension; titrate slowly. Weight gain and metabolic effects are less pronounced than with olanzapine or clozapine, but still monitor weight, lipids, and glucose.
Surital (thiamylal) is an ultra-short-acting barbiturate used for induction of anesthesia. Due to its high lipid solubility, onset of action is rapid (<30 seconds). It is contraindicated in porphyria and should be used with caution in patients with hepatic impairment, as it is metabolized in the liver. Extravasation causes tissue necrosis; use a large vein for IV administration. Respiratory depression and laryngospasm are common during induction. Surital has no analgesic properties and may cause myocardial depression at high doses. For short procedures, it provides rapid awakening but with potential residual sedation.
Take once daily without regard to meals. Swallow tablets whole, do not crush or chew.,May cause dizziness or drowsiness, especially when starting; avoid driving until you know how it affects you.,Do not stop taking suddenly without consulting your doctor, as this may cause withdrawal symptoms.,Report any restlessness, muscle stiffness, fever, or unusual movements to your doctor immediately.,Limit alcohol intake as it can increase side effects like drowsiness.,Inform your doctor of all medications you take, including over-the-counter drugs and supplements.,If you miss a dose, take it as soon as you remember unless it is almost time for the next dose; do not double up.,Regular blood tests may be needed to check for effects on blood sugar and cholesterol.
This medication is used to put you to sleep before surgery or certain procedures.,You may feel dizzy or drowsy for several hours after receiving this drug; do not drive or operate machinery for at least 24 hours.,Avoid alcohol for at least 24 hours after receiving this medication as it can increase side effects.,Inform your healthcare provider if you have a history of porphyria, liver disease, or respiratory problems.,Do not breastfeed for at least 24 hours after administration without consulting your doctor.,Notify your doctor immediately if you experience severe pain, redness, or swelling at the injection site.,You may experience temporary confusion or memory loss after waking up; this is normal and should resolve.
"Aripiprazole, a partial dopamine D2 and serotonin 5-HT1A agonist, may have its adverse effects potentiated by methsuximide, a succinimide anticonvulsant that inhibits CYP3A4. This can lead to increased aripiprazole plasma concentrations, raising the risk of extrapyramidal symptoms, sedation, and QT prolongation. Clinical outcomes include heightened neurotoxicity and potential for arrhythmias."
"Concurrent use of aripiprazole and clonazepam increases the risk of central nervous system (CNS) depression, including excessive sedation, dizziness, ataxia, and impaired cognitive or motor function. This additive pharmacodynamic interaction results from the combined depressant effects on the CNS mediated by GABAergic potentiation from clonazepam and dopaminergic/serotonergic modulation from aripiprazole. Patients may experience heightened somnolence, psychomotor slowing, and an increased risk of falls, particularly during initiation or dose escalation."
"Aripiprazole, an atypical antipsychotic with partial agonism at dopamine D2 and serotonin 5-HT1A receptors and antagonism at 5-HT2A receptors, can induce orthostatic hypotension, particularly during initial titration. This hypotensive effect may be additive when combined with moexipril, an ACE inhibitor that lowers blood pressure by inhibiting angiotensin II production. Concomitant use increases the risk of symptomatic hypotension, including dizziness, syncope, and falls, especially in elderly or volume-depleted patients."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ARIPIPRAZOLE vs SURITAL, answered by our medical review team.
ARIPIPRAZOLE is a Atypical Antipsychotic that works by Partial agonist at D2 and 5-HT1A receptors; antagonist at 5-HT2A receptors.. SURITAL is a Barbiturate Anesthetic that works by SURITAL (thiamylal) is an ultra-short-acting barbiturate that enhances GABA-A receptor activity, increasing chloride ion conductance and neuronal hyperpolarization, resulting in rapid induction of anesthesia.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ARIPIPRAZOLE and SURITAL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ARIPIPRAZOLE is: Oral: 10-15 mg once daily; initial and target dose 10-15 mg; maximum 30 mg/day. IM: 9.75 mg single dose, then 5.25-9.75 mg every 2 hours if needed; maximum 30 mg/day.. The standard adult dose of SURITAL is: Induction: 3-5 mg/kg IV bolus over 10-15 seconds. Maintenance: 0.5-1.5 mg/kg IV as needed for anesthesia. Also used as 0.2-0.4% solution for IV infusion at 0.5-2 mg/min.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ARIPIPRAZOLE and SURITAL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ARIPIPRAZOLE is classified as Category A/B. First trimester: Limited human data; animal studies show no teratogenicity at therapeutic doses, but increased risk of neural tube defects at high doses. Second/third trimesters: P. SURITAL is classified as Category C. Pregnancy Category D (positive evidence of human fetal risk). First trimester: Risk of congenital anomalies (limb defects, CNS malformations) based on animal studies and limited hu. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.